

PHARMACY COVERAGE GUIDELINE

OFF-LABEL USE OF CANCER MEDICATIONS

This Pharmacy Coverage Guideline (PCG):

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

Scope

- This PCG applies to Commercial and Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

Instructions & Guidance

- To determine whether a member is eligible for the Service, read the entire PCG.
- This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
- Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
- The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
- The “Description” section describes the Service.
- The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
- The “Resources” section lists the information and materials we considered in developing this PCG
- **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
- Information about medications that require prior authorization is available at www.azblue.com/pharmacy. You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to Pharmacyprecert@azblue.com.

Criteria:

- **Criteria for initial therapy:** An exception request for **Off-label Use of a Cancer medication** for the treatment of **another cancer** without a specific Pharmacy Coverage Guideline may be considered **medically necessary** and will be approved when **ALL** the following criteria are met:
 1. Prescriber is a physician specializing in the patient’s diagnosis or is in consultation with an Oncologist
 2. The requested agent has at least one FDA approved use for cancer
 3. **ONE** of the following:
 - a. The off-label use is recognized as safe and effective for the requested type of cancer **and** that is listed **and** supported by:
 - i. National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium with Categories of Evidence and Consensus of 1 and 2A

PHARMACY COVERAGE GUIDELINE

OFF-LABEL USE OF CANCER MEDICATIONS

- b. The off-label use is established from clinical trial(s) that have been published in peer reviewed professional medical journal(s) that has been submitted by the prescriber and **ALL** of the following apply:
 - i. At least two articles from major peer reviewed professional medical journals have recognized, based on scientific or medical criteria, the drug's safety and effectiveness for treatment of the indication for which the drug has been prescribed
 - ii. No article from a major peer reviewed professional medical journal has concluded, based on scientific or medical criteria, that the drug is unsafe or ineffective or that the drug's safety and effectiveness cannot be determined for the treatment of the indication for which the drug has been prescribed
 - iii. The literature meets the uniform requirements for manuscripts submitted to biomedical journals established by the international committee of medical journal editors or is published in a journal specified by the United States Department of Health and Human Services as acceptable peer reviewed medical literature pursuant to section 186(t)(2)(B) of the social security act (42 United States Code section 1395x(t)(2)(B))
4. Failure, contraindication or intolerance to established therapies per NCCN is verifiably documented
5. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or is not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
6. There are **NO** FDA-label contraindications for use of the requested drug
7. Individual does not have significant exclusions to use of the requested drug as outlined in product label (e.g., medical conditions, warnings or precaution for kidney dysfunction, hepatic dysfunction, other, etc.)
8. There are no significant interacting drugs
9. There are no benefit or contract exclusions that apply

Initial approval duration: 3 months

- **Criteria for continuation of coverage (renewal request):** Off-label Use of a Cancer medication for the treatment of **another cancer** without a specific Pharmacy Coverage Guideline is considered **medically necessary** and will be approved when **ALL** the following criteria are met (**samples are not considered for continuation of therapy**):
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation an Oncologist
 2. Individual's condition has responded while on therapy with response defined as there is no evidence of disease progression or unacceptable toxicity
 3. The individual is adherent with the medication

PHARMACY COVERAGE GUIDELINE

OFF-LABEL USE OF CANCER MEDICATIONS

4. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or is not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
5. Individual has not developed any contraindications or other significant adverse drug effects that may exclude to its continued use
6. Individual does not have significant exclusions to use the requested drug as outlined in product label (e.g., medical conditions, warnings or precaution for kidney dysfunction, hepatic dysfunction, other, etc.)
7. There are no significant interacting drugs
8. There are no benefit or contract exclusions that apply

Renewal duration: 12 months

- Requests for **Off-label Use of Cancer medications** are considered **experimental or investigational** and will not be covered when any **ONE** or more of the following criteria are met:
1. Lack of final approval from the appropriate governmental regulatory bodies (e.g., Food and Drug Administration); or
 2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes; or
 3. Insufficient evidence to support improvement of the net health outcome; or
 4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives; or
 5. Insufficient evidence to support improvement outside the investigational setting.

These indications include, *but are not limited to:*

- Treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration.

Description:

For FDA approved indications, also known as labeled indications, the FDA has reviewed and approved the medication for the specified use(s) for final marketing based on adequate, well-controlled clinical trials, which have documented safety and effectiveness. The use of an FDA approved medication for conditions, indications or in circumstances other than those approved by the FDA is known as “off-label use” (also referred to as unapproved use or unlabeled use). Unapproved or unlabeled uses include a variety of situations ranging from completely unstudied uses to scientifically investigated uses where the manufacturer has not asked the FDA for formal approval.

Off-label use of medications that have previously received FDA approval for marketing may be reviewed in any of the following ways: for medical necessity and/or investigational uses; during a review of a medication that requires prior authorization, during review of a medication due a non-formulary request for coverage, or during a review for any other prescription limitations.

ORIGINAL EFFECTIVE DATE: 11/17/2016 | ARCHIVE DATE: | LAST REVIEW DATE: 05/16/2024 | LAST CRITERIA REVISION DATE: 05/16/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

OFF-LABEL USE OF CANCER MEDICATIONS

An approved NDA (New Drug Application), ANDA (Abbreviated New Drug Application), or BLA (Biologic License Application) is considered final FDA-marketing approval for the purposes of this policy.

In certain instances, scientific evidence may support using a drug to treat a disease even if the drug's FDA approved label does not include those clinical conditions. In these circumstances, a compendia or scientific peer-reviewed literature specific for the indication in question may recommend uses beyond those included in the FDA approved labels. A compendium is a comprehensive listing of FDA approved drugs and biologics. Compendia include a summary of how each drug works in the body, as well as information for health care practitioners about proper dosing and whether the drug is recommended or endorsed for use in treating a specific disease.

Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting
[MedWatch Forms for FDA Safety Reporting | FDA](#)

National Comprehensive Cancer Network (NCCN):

Categories of Evidence and Consensus:

Category 1 recommendation	Based upon high-level evidence, there is uniform NCCN consensus that the recommendation is appropriate
Category 2A recommendation	Based upon lower-level evidence, there is uniform NCCN consensus that the recommendation is appropriate
Category 2B recommendation	Based upon lower-level evidence, there is NCCN consensus that the recommendation is appropriate
Category 3 recommendation	Based upon any level evidence, there is major NCCN disagreement that the recommendation is appropriate

IBM Micromedex:

Efficacy, Strength of Evidence and Strength of Recommendation definitions:

Strength Of Recommendation		
Class I	Recommended	The given test or treatment has been proven to be useful, and should be performed or administered.
Class IIa	Recommended, In Most Cases	The given test, or treatment is generally considered to be useful, and is indicated in most cases.
Class IIb	Recommended, In Some Cases	The given test, or treatment may be useful, and is indicated in some, but not most, cases.
Class III	Not Recommended	The given test, or treatment is not useful, and should be avoided.
Class Indeterminate	Evidence Inconclusive	
Strength Of Evidence		
Category A	Evidence is based on data derived from: Meta-analyses of randomized controlled trials with homogeneity with regard to the directions and degrees of results between individual studies. Multiple, well-done randomized clinical trials involving large numbers of patients.	
Category B	Evidence is based on data derived from: Meta-analyses of randomized controlled trials with conflicting conclusions with regard to the directions and degrees of results between individual studies. Randomized controlled trials that involved small numbers of patients or had significant methodological flaws (e.g., bias, drop-out rate, flawed analysis, etc.). Nonrandomized studies (e.g., cohort studies, case-control studies, observational studies).	

ORIGINAL EFFECTIVE DATE: 11/17/2016 | ARCHIVE DATE: | LAST REVIEW DATE: 05/16/2024 | LAST CRITERIA REVISION DATE: 05/16/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINE

OFF-LABEL USE OF CANCER MEDICATIONS

Category C	Evidence is based on data derived from: Expert opinion or consensus, case reports or case series.	
No Evidence		
Efficacy		
Class I	Effective	Evidence and/or expert opinion suggests that a given drug treatment for a specific indication is effective
Class IIa	Evidence Favors Efficacy	Evidence and/or expert opinion is conflicting as to whether a given drug treatment for a specific indication is effective, but the weight of evidence and/or expert opinion favors efficacy.
Class IIb	Evidence is Inconclusive	Evidence and/or expert opinion is conflicting as to whether a given drug treatment for a specific indication is effective, but the weight of evidence and/or expert opinion argues against efficacy.
Class III	Ineffective	Evidence and/or expert opinion suggests that a given drug treatment for a specific indication is ineffective.

Resources:

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.

ORIGINAL EFFECTIVE DATE: 11/17/2016 | ARCHIVE DATE: | LAST REVIEW DATE: 05/16/2024 | LAST CRITERIA REVISION DATE: 05/16/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.